CDK4 and breast carcinoma: Based on eventual development of CDK4/6 inhibitor resistance and there being no approved therapies to overcome the resistance, we established a preclinical model with palbociclib-resistant breast cancer to reveal mechanisms of CDK4/6 inhibitor resistance.